Incyte's Jakafi gets FDA approval to treat Graft vs Host Disease

The U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant.

from Reuters: Health News https://reut.rs/2YFQp4e
via IFTTT